LAVA Therapeutics N.V. Overview
Pro stress-test →LAVA Therapeutics N.V. is developing a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary Gammabody™ platform. As of November 2025, the company's structure has fundamentally changed, moving from a drug developer to an asset holding entity following its acquisition by XOMA Royalty Corporation.
Strategic Profile
Pro stress-test →LAVA is the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. All intellectual property and drug candidates, including the Gammabody® platform, are now under XOMA Royalty Corporation, with former LAVA Therapeutics N.V. shareholders retaining a right to 75% of net proceeds from the partnered and unpartnered programs via contingent value rights (CVRs).
Competitive Landscape
Pro stress-test →LAVA is currently the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. The company competes indirectly within the broader immuno-oncology and bispecific T-cell engager space, with differentiation via gamma-delta T cell platform specificity and partnerships with major pharmaceutical companies (Johnson & Johnson, Pfizer).
Industry Context
LAVA Therapeutics N.V. operates in Immuno-oncology therapeutics.
Key facts
Founded: 2016 · Headquarters: Utrecht, Netherlands · Employees: 32 (post-acquisition) · Revenue: $4.99M (12 months ending Sept 30, 2025)